Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension
- PMID: 33564260
- PMCID: PMC7866951
- DOI: 10.2147/PGPM.S291277
Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension
Abstract
Background: Amlodipine is one of the most used members of calcium channel blockers (CCB), available to treat hypertension. It is mainly metabolized by the Cytochrome P450 3A4/5 (CYP3A4/5) in the liver. Peripheral edema emerges as the major adverse drug reaction to amlodipine and is the primary reason for discontinuation of amlodipine therapy. However, genetic changes in CYP3A5 may lead to changes in the tolerability of amlodipine.
Purpose: In this study, we were interested whether variants in CYP3A5 have a role to play in amlodipine-induced peripheral edema.
Methods: A total number of 240 Chinese Han patients that have experienced hypertension were included in the study. Sixty-four patients had experienced amlodipine-induced peripheral edema, while the remaining 176 patients with no history of edema formed the control group. Twenty-four single-nucleotide polymorphisms (SNPs) of CYP3A5 gene were sequenced by targeted region sequencing method. The relationship of these genetic variants with amlodipine-induced peripheral edema risk was assessed using logistic regression.
Results: The allele frequencies of CYP3A5*1D (rs15524), CYP3A5*1E (rs4646453) and CYP3A5*3 (rs776746) were significantly different between cases and controls (P<0.05). The CYP3A5 *3/*3 (CC) or CYP3A5 *1D/*1D (AA) carriers showed an increased risk of amlodipine-induced peripheral edema in dominant model. Meanwhile, patients carrying CYP3A5 *1E (AC/AA) showed a reduced risk of peripheral edema. Furthermore, we found a strong linkage disequilibrium among rs15524, rs4646453 and rs776746.
Conclusion: Our study reveals for the first time that CYP3A5 *1D, *1E and *3 were associated with amlodipine-induced peripheral edema in Chinese Han patients with hypertension. However, further studies comprising larger number of samples, more related genes and other factors are wanted.
Keywords: CYP3A5; SNP; amlodipine; edema; pharmacogenomics.
© 2021 Liang et al.
Conflict of interest statement
All authors declare that they have no conflicts of interest for this work.
Figures
Similar articles
-
Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects.Mol Genet Genomic Med. 2020 May;8(5):e1201. doi: 10.1002/mgg3.1201. Epub 2020 Mar 5. Mol Genet Genomic Med. 2020. PMID: 32134573 Free PMC article.
-
Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.Ther Clin Risk Manag. 2014;10:17-26. doi: 10.2147/TCRM.S55512. Epub 2013 Dec 20. Ther Clin Risk Manag. 2014. PMID: 24379677 Free PMC article. Review.
-
Polymorphisms in the CYP3A5 gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation.Pharmacogenomics. 2021 Sep;22(14):903-912. doi: 10.2217/pgs-2021-0083. Epub 2021 Sep 15. Pharmacogenomics. 2021. PMID: 34523354
-
Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.Epilepsy Res. 2015 Nov;117:52-7. doi: 10.1016/j.eplepsyres.2015.09.001. Epub 2015 Sep 9. Epilepsy Res. 2015. PMID: 26421491
-
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.Clin Pharmacokinet. 2010 Mar;49(3):141-75. doi: 10.2165/11317350-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20170205 Review.
Cited by
-
Personalized antihypertensive treatment guided by pharmacogenomics in China.Cardiovasc Diagn Ther. 2022 Oct;12(5):635-645. doi: 10.21037/cdt-22-154. Cardiovasc Diagn Ther. 2022. PMID: 36329971 Free PMC article.
-
A Roadmap for Using Causal Inference and Machine Learning to Personalize Asthma Medication Selection.JMIR Med Inform. 2024 Apr 17;12:e56572. doi: 10.2196/56572. JMIR Med Inform. 2024. PMID: 38630536 Free PMC article.
-
Very important pharmacogenetic variants landscape and potential clinical relevance in the Zhuang population from Yunnan province.Sci Rep. 2024 Mar 29;14(1):7495. doi: 10.1038/s41598-024-58092-w. Sci Rep. 2024. PMID: 38553524 Free PMC article.
-
Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients.Front Pharmacol. 2022 Mar 14;13:848804. doi: 10.3389/fphar.2022.848804. eCollection 2022. Front Pharmacol. 2022. PMID: 35359836 Free PMC article.
-
A Multivariate prediction model for amlodipine therapeutic efficacy in pediatric primary hypertension.Front Endocrinol (Lausanne). 2025 Feb 11;16:1542276. doi: 10.3389/fendo.2025.1542276. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40007810 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources